Cormedix Inc (CRMD) Stock Price, Quote & News

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 517 9500

Website: cormedix.com

Address:

389 Interpace Pkwy, Suite 450, Parsippany, United States

CaliEmpress Jul. 3 at 4:24 PM

$CRMD We now know they are gearing up for a merger, acquisition or buyout. The question remains is it $TLPH or Big Pharma?

2 · Reply

mrty Jul. 3 at 3:33 PM

$CRMD Always fun to check this websites valuation for CorMedix. I'm sure we would all be happy with this outcome...Happy 4th! and GLTA https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/valuation

1 · Reply

Noname2022 Jul. 3 at 2:09 AM

$CRMD

1 · Reply

GardeningGirl Jul. 3 at 2:03 AM

$CRMD

2 · Reply

Gencooliveoil Jul. 2 at 11:11 PM

$CRMD Both company Liz wirked previously were taken over. Gemphire Therapeutics Merged with NeuroBo Pharmaceuticals: In December 2019, Gemphire Therapeutics completed a reverse merger with the privately held biotech company NeuroBo Pharmaceuticals. Following the transaction, NeuroBo became the surviving entity, and the combined company began trading on the Nasdaq under the ticker symbol NRBO.Accelovance Merged with Linical: In April 2018, Accelovance, a clinical development Contract Research Organization (CRO), entered a merger agreement with Linical Co., Ltd., a prominent global CRO based in Japan. This merger was designed to combine Linical's presence in Asia and Europe with Accelovance's established clinical trials network in the United States.

0 · Reply

Andy1063 Jul. 2 at 10:05 PM

$CRMD Seckler lost out on ~133,000 RSU's by leaving. So, Im guessing he either received a MUCH better job offer or he was sent packing...

0 · Reply

Derek22us Jul. 2 at 9:50 PM

$CRMD Happy 4th and 250th to all real, non margined share OWNERS who do not aid and abet short sheisters who (supposedly) have to borrow shares. Nice to get some of our stolen money back. Lets get to $9 and above as we advance upwards. Good to see management shakeup after the proxy voting that i believe showed widespread disapproval of the team. Time also to trim fat that is always present in any takeover.

0 · Reply

focafoca99 Jul. 2 at 9:04 PM

$CRMD installed its new chief operating and commercial officer, Elizabeth Hurlburt. https://www.rapidticker.com/news/crmd-sec-filing-def42f

0 · Reply

Noname2022 Jul. 2 at 8:55 PM

$CRMD

3 · Reply

TwongStocks Jul. 2 at 8:38 PM

$CRMD Executive management changes. Michael Seckler, EVP and Chief Commercial Officer, has left CRMD. Elizabeth Hurlburt, current COO, has taken on CCO duties. https://www.sec.gov/ix?doc=/Archives/edgar/data/1410098/000141009826000040/crmd-20260629.htm "On June 29, 2026, CorMedix Inc. (the “Company”) effected a change in its executive leadership structure, whereby the Company’s Board of Directors has appointed Elizabeth Hurlburt, currently the Chief Operating Officer, to the newly created role of Chief Operating and Commercial Officer where she will have functional oversight of all commercial functions in addition to medical affairs, regulatory and clinical. Ms. Hurlburt will continue to report to Chairman & CEO Joseph Todisco in this newly created role. As part of this change in executive leadership structure, Michael Seckler has left the Company."

2 · Reply

CorMedix Transcript: AGM 2026

2026-06-08T13:00:11.000Z - 26 days ago

CorMedix announces United States Court of Appeals affirms patent judgements

Jun 8, 2026, 8:30 AM EDT - 26 days ago

U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

Jun 3, 2026, 4:20 PM EDT - 4 weeks ago

CorMedix Transcript: Jefferies Global Healthcare Conference 2026

May 22, 2026, 7:00 AM EDT - 6 weeks ago

CorMedix Slides: Corporate presentation

May 20, 2026, 11:00 AM EDT - 6 weeks ago

CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 15, 2026, 8:30 AM EDT - 7 weeks ago

Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

May 14, 2026, 8:30 AM EDT - 7 weeks ago

CorMedix Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

CorMedix Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

CorMedix Quarterly report: Q1 2026

2026-05-14T11:53:51.000Z - 7 weeks ago

CorMedix reports Q1 EPS 43c, consensus 33c

2026-05-14T11:47:54.000Z - 7 weeks ago

CorMedix raises FY26 revenue view to $325M-$345M from $300M-$320M

May 14, 2026, 7:30 AM EDT - 7 weeks ago

Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 8:30 AM EDT - 2 months ago

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

CorMedix Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

CorMedix Proxy statement: Proxy filing

2026-04-28T19:40:19.000Z - 2 months ago

Citizens healthcare analysts hold an analyst/industry conference call

2026-04-28T11:56:23.000Z - 2 months ago

CorMedix price target raised to $14 from $13 at RBC Capital

2026-04-27T12:05:37.000Z - 2 months ago

CorMedix announces ReSPECT clinical trial met primary endpoint

Apr 27, 2026, 7:30 AM EDT - 2 months ago

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Apr 17, 2026, 8:00 AM EDT - 2 months ago

CorMedix Proxy statement: Proxy filing

Apr 14, 2026, 3:00 PM EDT - 2 months ago

CorMedix Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:30 AM EDT - 3 months ago

CorMedix to Participate in Needham Virtual Healthcare Conference

Mar 11, 2026, 9:35 AM EDT - 4 months ago

CorMedix Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:00 PM EDT - 4 months ago

CorMedix Transcript: Leerink Global Healthcare Conference 2026

Mar 7, 2026, 6:00 AM EST - 4 months ago

CorMedix Slides: Corporate presentation

2026-03-06T22:20:58.000Z - 4 months ago

CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M

2026-03-06T17:05:52.000Z - 4 months ago

CorMedix price target lowered to $13 from $15 at Leerink

Mar 5, 2026, 12:58 PM EST - 4 months ago

CorMedix stock drops after earnings: is this dip a buy before key catalyst?

Mar 5, 2026, 8:30 AM EST - 4 months ago

CorMedix Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

CorMedix Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

CorMedix Earnings release: Q4 2025

2026-03-05T12:36:24.000Z - 4 months ago

CorMedix reports Q4 EPS 16c vs 20c last year

Mar 5, 2026, 7:30 AM EST - 4 months ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 2, 2026, 8:30 AM EST - 4 months ago

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

Feb 12, 2026, 8:30 AM EST - 5 months ago

CorMedix to Participate in Upcoming Investor Conferences

Feb 10, 2026, 1:00 PM EST - 5 months ago

CorMedix Transcript: Investor Day 2026

Feb 10, 2026, 1:00 PM EST - 5 months ago

CorMedix Slides: FY 2026

2026-02-02T13:35:15.000Z - 5 months ago

CorMedix board authorizes share repurchase program of up to $75M

Feb 2, 2026, 8:30 AM EST - 5 months ago

CorMedix Therapeutics Announces Share Repurchase Program

Jan 29, 2026, 8:30 AM EST - 5 months ago

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

2026-01-23T11:10:42.000Z - 5 months ago

CorMedix price target lowered to $13 from $18 at H.C. Wainwright

2026-01-21T11:35:46.000Z - 5 months ago

CorMedix price target lowered to $13 from $22 at RBC Capital

Jan 12, 2026, 7:30 PM EST - 6 months ago

CorMedix Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 10, 2026, 7:00 AM EST - 6 months ago

CorMedix Slides: Corporate presentation

Jan 9, 2026, 8:30 AM EST - 6 months ago

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 1:37 PM EST - 6 months ago

Why is CorMedix stock crashing today: is it worth buying on the dip?

2026-01-08T17:45:22.000Z - 6 months ago

CorMedix price target lowered to $16 from $20 at Truist

2026-01-08T13:17:12.000Z - 6 months ago

CorMedix sees FY26 revenue $300M-$320M

Jan 8, 2026, 8:05 AM EST - 6 months ago

CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:00 AM EST - 6 months ago

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

Dec 18, 2025, 8:00 AM EST - 7 months ago

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

Nov 12, 2025, 4:05 PM EST - 8 months ago

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

TLPH

Nov 12, 2025, 8:30 AM EST - 8 months ago

CorMedix Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

CorMedix Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

CorMedix Earnings release: Q3 2025

Nov 12, 2025, 7:30 AM EST - 8 months ago

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

Oct 31, 2025, 8:30 AM EDT - 8 months ago

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

Oct 24, 2025, 8:00 AM EDT - 9 months ago

CorMedix Proxy statement: Proxy Filing

Oct 23, 2025, 8:30 AM EDT - 9 months ago

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

Oct 22, 2025, 4:05 PM EDT - 9 months ago

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 20, 2025, 9:42 AM EDT - 9 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC RANI RAPT

Oct 20, 2025, 7:30 AM EDT - 9 months ago

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

Oct 14, 2025, 8:00 AM EDT - 9 months ago

CorMedix Proxy statement: Proxy Filing

Sep 30, 2025, 8:00 AM EDT - 9 months ago

CorMedix Registration statement: Registration Filing

Sep 29, 2025, 8:30 AM EDT - 9 months ago

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

Sep 15, 2025, 8:00 AM EDT - 10 months ago

CorMedix Proxy statement: Proxy Filing

Sep 10, 2025, 10:45 AM EDT - 10 months ago

CorMedix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 8:30 AM EDT - 10 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH

Sep 8, 2025, 8:30 AM EDT - 10 months ago

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

TLPH

Sep 5, 2025, 8:35 AM EDT - 10 months ago

CorMedix Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 10 months ago

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

Aug 7, 2025, 10:49 AM EDT - 11 months ago

CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 7:30 AM EDT - 11 months ago

CorMedix Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 11 months ago

CorMedix Earnings release: Q2 2025

Aug 7, 2025, 7:10 AM EDT - 11 months ago

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

Aug 7, 2025, 7:00 AM EDT - 11 months ago

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 27, 2025, 8:00 AM EDT - 1 year ago

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

Jun 26, 2025, 4:01 PM EDT - 1 year ago

CorMedix Inc. Announces Proposed Public Offering of Common Stock

Jun 23, 2025, 7:30 AM EDT - 1 year ago

CorMedix inc. Announces Customer Implementation

Jun 5, 2025, 3:45 PM EDT - 1 year ago

CorMedix Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

May 21, 2025, 3:05 PM EDT - 1 year ago

CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

May 8, 2025, 11:00 AM EDT - 1 year ago

CorMedix Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings release: Q1 2025

May 6, 2025, 7:30 AM EDT - 1 year ago

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing

Apr 8, 2025, 2:15 PM EDT - 1 year ago

CorMedix Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

Apr 2, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

CaliEmpress Jul. 3 at 4:24 PM

$CRMD We now know they are gearing up for a merger, acquisition or buyout. The question remains is it $TLPH or Big Pharma?

2 · Reply

mrty Jul. 3 at 3:33 PM

1 · Reply

Noname2022 Jul. 3 at 2:09 AM

$CRMD

1 · Reply

GardeningGirl Jul. 3 at 2:03 AM

$CRMD

2 · Reply

Gencooliveoil Jul. 2 at 11:11 PM

0 · Reply

Andy1063 Jul. 2 at 10:05 PM

$CRMD Seckler lost out on ~133,000 RSU's by leaving. So, Im guessing he either received a MUCH better job offer or he was sent packing...

0 · Reply

Derek22us Jul. 2 at 9:50 PM

0 · Reply

focafoca99 Jul. 2 at 9:04 PM

$CRMD installed its new chief operating and commercial officer, Elizabeth Hurlburt. https://www.rapidticker.com/news/crmd-sec-filing-def42f

0 · Reply

Noname2022 Jul. 2 at 8:55 PM

$CRMD

3 · Reply

TwongStocks Jul. 2 at 8:38 PM

2 · Reply

SweStonk Jul. 2 at 8:34 PM

$CRMD Another day with good momentum. This is building up nicely 🤑 $XBI

0 · Reply

ReturnOfEsquire Jul. 2 at 8:02 PM

$CRMD Another solid day. We need to break and hold 10. That allows more tutes and platforms access.

0 · Reply

Derek22us Jul. 2 at 7:56 PM

$CRMD 700 and 1100 Controlling the price as we near the close. Assshole price droppers active. Would like to see them getting nuked as approach the close.

0 · Reply

AndyR22 Jul. 2 at 7:10 PM

$CRMD My prediction: By the end of the year the AI bubble will deflate a bit, the S&P and Dow will fall and investors will rush to biotech and pharma as a safe haven. When it happens, CRMD will drop at first with everything else and then start a rapid climb to $12. $PFE will be at $32 by EOY.

0 · Reply

drew64 Jul. 2 at 7:09 PM

$CRMD DVA moving higher, again today😎🍻🤙🏼

0 · Reply

SweStonk Jul. 2 at 3:26 PM

$CRMD You have to dare to believe. If we all believe there is nothing stopping us! Great fundamentals extremely low SP... Believe in yourself, believe in your DD and keep slapping that ask every month and we will all be rewarded handsomely. Let all show these bears there is no room for them here any longer 😎

1 · Reply

Mr_Pithy Jul. 2 at 3:18 PM

$CRMD MR. TWO FACED.

1 · Reply

ReturnOfEsquire Jul. 2 at 2:45 PM

$CRMD This...aged...poorly.

1 · Reply

CaliEmpress Jul. 2 at 2:42 PM

$CRMD Companies often change auditors for reasons such as: * wanting a larger international audit firm, * supporting company growth, * improving credibility with institutional investors, * or preparing for a larger commercial stage. Hmmmm all the above?

1 · Reply

CRMDepressed Jul. 2 at 2:31 PM

$CRMD $20 realistic?

3 · Reply

SweStonk Jul. 2 at 2:27 PM

$CRMD Keeping the momentum and going higher and higher. Either you are in or out cause this wont wait for u 🍻 These prices are nothing compared to our real value. When that day come I will be laughing all the way to my new Catamaran 😉

0 · Reply

VictoryFormation Jul. 2 at 2:14 PM

$CRMD Welcome to the third quarter, where visibility beyond the second half revenue cliff starts to come into play.

1 · Reply

Market Cap	686.46M
Revenue (ttm)	311.71M
Net Income (ttm)	163.06M
EPS (ttm)	N/A
PE Ratio	4.48
Forward PE	16.61
Profit Margin	52.31%
Debt to Equity Ratio	0.00

Volume	1,043,900
Avg Vol	1,407,384
Day's Range	N/A - N/A
Shares Out	78.45M
Stochastic %K	80%
Beta	1.48
Analysts	Strong Sell
Price Target	$14.00